Literature DB >> 2257203

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

N H Mulder1, P H Willemse, H Schraffordt Koops, E G de Vries, D T Sleijfer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2257203      PMCID： PMC1971582          DOI： 10.1038/bjc.1990.427

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; J M Smit; E G De Vries; P H Willemse; H S Koops
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

2.  Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.

Authors:  E T Creagan; D L Ahmann; S Frytak; H J Long; M N Chang; L M Itri
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

Review 3.  Systemic chemotherapy for metastatic melanoma.

Authors:  E F Mc Clay; M J Mastrangelo
Journal:  Semin Oncol       Date:  1988-12       Impact factor: 4.929

4.  Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; M J Samson; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.

Authors:  D Khayat; F Lokiec; J P Bizzari; M Weil; L Meeus; M Sellami; J Rouesse; P Banzet; C Jacquillat
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701
  5 in total
  3 in total

1.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.

Authors:  N H Mulder; E G de Vries; D T Sleijfer; H Schraffordt Koops; P H Willemse
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

3.  Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Authors:  N H Mulder; W T van der Graaf; P H Willemse; H S Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.